drugset / Trial / NCT00715702

Safety Study of AZD5672 in Renally Impaired Subjects

NCT00715702

Phase 1 Completed 40 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to investigate the pharmacokinetics of a single dose of AZD5672 in patients with renal impairment by comparing with healthy volunteers

Timeline

Start
2008-07
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5672 Small molecule 100 mg Oral